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Abstract. We studied effects of compliance on the impact of mass drug administration (MDA) with diethylcarbam-
azine and albendazole for lymphatic filariasis (LF) in an Egyptian village. Baseline microfilaremia (mf) and filarial
antigenemia rates were 11.5% and 19.0%, respectively. The MDA compliance rates were excellent (> 85%). However,
individual compliance was highly variable; 7.4% of those surveyed after five rounds of MDA denied having ever taken
the medications and 52.4% reported that they had taken all five doses. The mf and antigenemia rates were 0.2% and
2.7% in those who reported five doses of MDA and 8.3% and 13.8% in those who reported zero doses. There was no
significant difference in residual infection rates among those who had taken two or more doses. These results underscore
the importance of compliance for LF elimination programs based on MDA and suggest that two ingested doses of MDA
are as effective as five doses for reducing filariasis infection rates.
INTRODUCTION
The Global Program to Eliminate Lymphatic Filariasis
(GPELF) has the ambitious goal of eliminating LF in all dis-
ease-endemic areas by the year 2020.1 The GPELF aims to
permanently interrupt transmission of LF with a program that
is largely based on mass drug administration (MDA) with
antifilarial medications that reduce microfilaremia (mf) rates
in communities to levels below those needed for sustained
transmission by mosquitoes. The MDA programs were initi-
ated in several countries in 2000. The global program rapidly
expanded, and more than 380 million people in 42 countries
received MDA for LF in 2005 (the last year with reported
numbers).2 With a stated goal of providing MDA to some 1.3
billion people by the year 2020, this program is easily the
largest infectious disease intervention that has ever been at-
tempted based on MDA.
Filarial worms have long life spans, and antifilarial medi-
cations do not work unless they are ingested. Mathematical
models that simulate LF transmission3,4 and GPELF guide-
lines emphasize the importance of achieving high MDA cov-
erage rates.5,6 Reported MDA coverage rates vary,7–9 and
compliance rates (percentage of people who report having
taken the medications) are sometimes much lower than cov-
erage rates (percentage of people who received the medica-
tions) reported by public health authorities.10 Compliance
rates have decreased after several rounds of MDA in some
areas11 but have increased in others.8,12 A number of factors
contribute to MDA noncompliance, including ignorance or
indifference in the target population regarding LF, fear of
adverse events from treatment, distrust of government pro-
grams, and failure to receive the medications.8,10,13
Bancroftian filariasis has been endemic in Egypt for centu-
ries.14 A 1993 publication estimated that 250,000 people were
infected and 2.5 million at risk for infection at that time in
eight governorates, mostly in the Nile river delta region
(Lower Egypt) and in Giza.15 The Egyptian Ministry of
Health and Population (MOHP) initiated a national program
to eliminate LF in 2000.16 This was one of the first national LF
elimination programs based on the GPELF strategy. The pro-
gram was planned and coordinated by MOHP with technical
assistance from the academic community and the World
Health Organization. Directly observed MDA (DO-MDA)
was conducted in all known filariasis-endemic localities in the
country with annual doses of diethylcarbamazine (DEC, 6
mg/kg) with albendazole (400 mg). Local health teams from
MOHP primary health care units distributed medications on
a house-to-house basis, with directly observed ingestion of
tablets when possible. Teams visited houses a second time to
reach household members who were absent on the first visit,
and separate teams were based in primary health care units to
provide MDA to people who were missed during home visits
by the regular MDA distribution teams. The program was
supported by a broad-based publicity campaign, and excellent
MDA coverage rates were achieved.17,18 We have previously
reported results of a prospective study of the impact of five
rounds of MDA on filariasis endemicity and transmission in
sentinel Egyptian villages.19 The present report addresses the
critical issue of the effects of varying levels of compliance on
the impact of MDA. Our results underscore the importance
of compliance for LF elimination programs based on MDA
and suggest that two ingested doses of MDA are as effective
as five ingested doses for reducing filarial infection rates.
METHODS
Study design. The study was conducted in two adjacent sec-
tors of Azizia village (Kafr El Bahary and Kafr El Qebly),
which is located in Giza Governorate approximately 40 km
southwest of Cairo. This village had the highest known mf
prevalence in Egypt just prior to initiation of the national
filariasis elimination program. The two village sectors were
mapped, and houses were numbered with painted numbers.
We conducted a cross-sectional survey for W. bancrofti infec-
tion (see below) just prior to the first round of MDA with
repeated surveys 6–8 months after each round of MDA. The
total population of the study area was approximately 10,000.
Each survey studied approximately 1,000 people older than
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five years of age in 200 households that were randomly se-
lected each year using SPSS software (SPSS Inc., Chicago,
IL). Survey teams comprised of a physician, a technician, and
a local health worker visited houses in the early evening. Field
personnel recorded demographic and MDA compliance in-
formation (for post-MDA surveys) on preprinted forms. Par-
ents provided treatment histories for their children.
Compliance rates were estimated by dividing the number of
study participants in survey households who reported having
taken DEC and albendazole in the previous round of MDA
by the total number of study participants who lived in these
houses.
Tests for Wuchereria bancrofti infection. Finger prick
blood samples were collected for detection of W. bancrofti
antigenemia (circulating filarial antigenemia [CFA]) with
rapid-format card tests.20,21 Immunochromatographic card
tests for filariasis (AMRAD, French’s Forest, New South
Wales, Australia) were used for the first three surveys and
Filariasis Now cards (Binax, Portland, ME) were used for
surveys after MDA rounds 3–5. Subjects with positive filari-
asis antigen test results were tested for mf by membrane fil-
tration of 1 mL of venous blood collected between 9:00 PM
and 1:00 AM as previously described.22 The mf prevalence rate
was defined as the number of people with mf divided by the
number of people tested for filarial antigenemia. This rate
slightly underestimates the true mf prevalence rate because
the sensitivity of the antigen card test in mf carriers (as de-
tected by membrane filter) is approximately 95%.20,23
Consent procedures and ethical review. Survey teams ex-
plained the study to study participants and obtained informed
consent from all adult participants. Child participation re-
quired consent of at least one parent and the assent of the
child. The study protocol was reviewed and approved by in-
stitutional review boards at Washington University School of
Medicine (St. Louis, MO) and at Ain Shams University
(Cairo, Egypt). The Egyptian Ministry of Health and Popu-
lation also reviewed and approved the study.
Statistical methods. Data entry was performed with
EpiInfo software (version 6)24 with field limits and double
data entry. We performed statistical analyses using SAS 9.1
for Windows (SAS, Cary, NC) procedures PROC GLIMMIX
to adjust for correlation within household (random effect)
and to fit mixed logistic regression models. Age and sex of
individual subjects were included as fixed effects in the mod-
els to test their significance. Because data were collected each
year for six years, linear contrasts were used to increase
power to compare infection and MDA compliance at differ-
ent times for different numbers of MDA doses taken.
RESULTS
Baseline filarial infection prevalence rates. Baseline mf and
filarial antigenemia rates were 11.5% and 19.0%, respec-
tively. Baseline filarial infection rates are shown by age and
sex in Figure 1. The shapes of the histograms are similar for
both parameters, although CFA rates were consistently
higher than mf rates, as expected. Infection rates varied sig-
nificantly by age (P < 0.001 for both mf and CFA) with peak
prevalence rates between the ages of 16 and 35 years. This
difference was mostly caused by decreased rates in young
children, and there was no significant age effect when the
youngest age group was excluded from the analysis. Although
infection rates tended to be higher in males than in females,
these differences were not statistically significant (P  0.30
for mf and P  0.08 for CFA).
Compliance with MDA. Overall compliance rates for the
surveyed population were 86.7%, 95.5%, 90.1%, and 88.8%
for MDA rounds 1–4. Thus, there was no significant decrease
in reported compliance rates over time. Compliance rates did
not vary significantly by age group or sex. Table 1 shows the
cumulative number of doses of annual MDA that people re-
ported having taken after each round of MDA. Note that
52% of the people surveyed after MDA round 5 reported
having taken all five doses. The percentages of subjects who
reported having taken only zero or one dose of MDA did not
decrease significantly after MDA round 3.
Relationships between the number of MDA doses taken
and residual infection rates. Figure 2 shows relationships be-
tween reported MDA compliance and mf and CFA rates after
MDA round 5. People who reported that they had taken no
MDA had a higher mf rate than those who reported that they
had taken one dose of MDA (P 0.002); CFA rates were not
significantly different in these two groups. The mf and CFA
rates were similar in those who reported that they had taken
two or more annual doses of MDA, and these rates were
significantly lower than those in people who reported that
they had taken zero or one dose of MDA (P  0.006 for mf
and P < 0.0001 for CFA). Reductions in infection rates after
MDA were not significantly different by age group or sex.
Relative infection rates after MDA. Table 2 shows infec-
tion rates relative to baseline rates according to the reported
cumulative number of annual MDA doses taken when people
FIGURE 1. Baseline (before mass drug administration), age-
specific prevalence rates for A, microfilaremia and B, filarial antigen-
emia in males (black bars) and females (gray bars) in Egypt.
EL-SETOUHY AND OTHERS1070
were interviewed after MDA round 5. Filarial antigenemia
and mf rates in people who reported zero doses of MDA were
lower than baseline rates, but these decreases were not sta-
tistically significant (P  0.59 and 0.32, respectively). Anti-
genemia and mf rates in those who reported taking one dose
of MDA were significantly lower than baseline rates (P 
0.02 and P 0.03, respectively). Antigenemia and mf rates in
those who reported taking two or more doses of MDA were
significantly lower than baseline rates (P  0.01 and P 
0.005, respectively). Relative mf rates were lower than rela-
tive CFA rates for people with the same MDA compliance
histories.
DISCUSSION
The purpose of this study was to examine the effect of
compliance on the impact of MDA on filariasis infection rates
in a filariasis-endemic Egyptian community. The MDA com-
pliance rates were excellent in this community and consistent
with generally high coverage rates reported by the Egyptian
MOHP.17,18 We did not observe a decrease in compliance
rates in later years of the study.
Two major factors contributed to high MDA compliance
rates reported in this study. The Egyptian government’s social
mobilization efforts emphasized the importance of LF as a
disabling disease that could be eliminated by a time-limited,
focused effort.16 Education programs had simple messages
that were delivered with posters in villages, with announce-
ments in places of worship, and with skits and advertisements
on television and radio. Elimination of LF was also promoted
in schools. Children were given special comic books and other
educational materials regarding LF elimination at school,25
and children may have been important advocates for the LF
elimination program in their homes and villages. It is impor-
tant to note that health education messages were delivered
prior to the first round of MDA and reinforced just prior to
each of the subsequent rounds.
The method of MDA delivery (DO-MDA) was critically
important for ensuring high compliance in our study area and
more generally in Egypt. The DO-MDA was distributed by
local health teams comprised of physicians, nurses, and other
workers from primary health care units; trusted, local profes-
sional teams took the time to deliver the medications to each
house with directly observed ingestion of medications in most
cases. Compliance rates would not have been as high or as
sustained if strangers from the provincial capital had arrived
in vans once per year to drop off cartons of tablets in village
markets. Other investigators have emphasized the impor-
tance of community involvement for achieving high MDA
compliance rates in filariasis elimination programs.26–28 We
believe that the GPELF should consider revising program
manager guidelines to emphasize house-to-house DO-MDA
as the preferred method for distribution of MDA in LF elimi-
FIGURE 2. A, Microfilaremia and B, filarial antigenemia rates ac-
cording to compliance with mass drug administration (MDA) as re-
ported in interviews conducted 6–8 months after the last round of
MDA in Egypt.
TABLE 2
Residual filarial infection rates relative to baseline rates according to
the reported total number of mass drug administration (MDA)




relative to baseline (%)
Microfilaremia rate relative
to baseline (%)
0 79 65.9 65.4
1 57 81.0 15.1
2 100 5.3 0
3 162 22.5 5.3
4 109 14.3 0
5 557 14.0 1.5
* Compliance with MDA was based on interviews conducted 6–8 months after the fifth
round of MDA.
TABLE 1
Reported compliance with mass drug administration (MDA) for lymphatic filariasis in the study area in Egypt*
Cumulative no. (%) of annual MDA doses ingested
MDA Round 0 1 2 3 4 5 Total
1 178 (17.59) 834 (82.41) 1,012
2 44 (4.29) 153 (14.93) 828 (80.78) 1,025
3 53 (5.25) 84 (8.33) 165 (16.35) 707 (70.07) 1,009
4 80 (7.17) 124 (11.12) 271 (24.30) 137 (12.29) 503 (45.11) 1,115
5 79 (7.42) 57 (5.36) 100 (9.40) 162 (15.23) 109 (10.24) 557 (52.35) 1,064
* Values are the no. of people (%) who reported having taken different numbers of doses of MDA in interviews conducted 6–8 months after each round of MDA.
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nation programs. Although DO-MDA requires more re-
sources than other distribution methods, it should pay for
itself if it can improve compliance rates enough to reduce the
number of MDA rounds required for LF elimination.
Our results confirm that MDA with DEC and albendazole
can be highly effective for reducing LF infection rates in com-
munities. Although GPELF guidelines call for four to six
rounds of MDA with high coverage for LF elimination pro-
grams,5,6 there is some uncertainty in the LF community re-
garding the number of rounds of MDA that are actually
needed to achieve LF elimination (reduction of infection
rates to levels below those required for sustained transmis-
sion). Mathematical models suggest that this number will vary
in different locations because of variability in factors such as
the baseline infection rate, vectorial capacity, efficacy of the
MDA regimen used, and MDA compliance rates.3,4 MDA
programs never achieve 100% compliance, and clinical trials
have shown that W. bancrofti infections are only rarely
cleared by a single dose of DEC with albendazole.22,29 Addi-
tional rounds of MDA should improve cumulative compli-
ance rates (the percentage of people who have taken one or
more doses of MDA) and improve mf clearance rates in in-
fected people.30 Although five rounds is a reasonable guide-
line for planning MDA programs, GPELF guidelines call for
repeating MDA until targets are reached.6 We believe that it
may be possible to eliminate LF with less than five rounds of
MDA in some areas, but six rounds will not do the job if
compliance rates are low.
Our results clearly show the important influence of MDA
compliance on residual infection rates after MDA. It was not
surprising that residual infection rates were highest in people
who reported that they had never taken MDA. Although a
single dose of MDA had a significant impact on mf, two doses
of MDA were better than one and as good as five doses for
clearing mf. In addition, although these results could be af-
fected by inaccurate recall of MDA compliance in our study
population, they are consistent with data from a clinical trial
that reported dramatic increases in mf clearance rates after
heavily infected subjects were treated with two or more an-
nual doses of DEC with albendazole.22,30 Thus, our data em-
phasize that MDA programs should focus on the objective of
delivering two or more doses of DEC with albendazole to a
high percentage of their target populations. Note that this
does not mean that LF elimination can be achieved with two
rounds of MDA. It is also important to consider that these
results from Egypt might not apply to all LF-endemic areas.
Additional MDA doses might be needed to achieve high rates
of mf clearance in areas with higher baseline LF prevalence
rates and infection intensities.
Filarial infection rates should decrease over time in people
who do not take antifilarial medications after LF transmission
is interrupted in their area by MDA. Thus, MDA should
indirectly benefit noncompliant people because of a “herd
treatment effect.” This effect may occur because filarial
worms have a finite life span (estimated to be 7–10 years); old
worms die, and new infections should be prevented by MDA.
We observed a trend toward reduced infection rates in non-
compliant people after several rounds of MDA, but this
change was not statistically significant. This finding may have
been observed because our study was underpowered to ob-
serve this decrease; only 79 of 1,064 people studied after
MDA round 5 reported that they had never taken MDA.
The flip side of the herd treatment effect is that systemati-
cally noncompliant people (al-rafidin in Arabic) threaten the
success of MDA programs, especially in areas with high base-
line infection rates. Other investigators have grappled with
this problem.8,9 It is expensive to provide supplemental
rounds of MDA to entire populations in hopes of treating
people who have been missed in the early rounds. Additional
rounds of MDA after rounds 4 or 5 mostly treat people who
do not need further treatment and miss most of the system-
atically noncompliant population. Further work is needed to
understand the reasons for noncompliance with MDA, to re-
fine health education message(s) to target the noncompliers,
and to implement alternative strategies for crossing the finish
line. These might include anti-mosquito measures, DEC-
impregnated salt, or test and treat activities that permit se-
lective treatment of people with residual infections.
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